Aspirin as a chemoprevention agent for colorectal cancer.

Hdl Handle:
http://hdl.handle.net/10147/296530
Title:
Aspirin as a chemoprevention agent for colorectal cancer.
Authors:
Lee, Chun Seng; McNamara, Deirdre; O'Morain, Colm A
Affiliation:
Department of Clinical Medicine, Trinity Centre for Health sciences, Adelaide and Meath, Hospital, Dublin, Ireland. chunseng75@yahoo.co.uk
Citation:
Aspirin as a chemoprevention agent for colorectal cancer. 2012, 13 (9):1313-22 Curr. Drug Metab.
Journal:
Current drug metabolism
Issue Date:
Nov-2012
URI:
http://hdl.handle.net/10147/296530
PubMed ID:
22493984
Abstract:
Colorectal cancer (CRC) is one of the leading causes of mortality in the western world. It is widely accepted that neoplasms such as colonic polyps are precursors to CRC formation; with the polyp-adenoma-carcinoma sequences well described in medical literature [1, 2]. It has been shown that Aspirin and other non-steroid anti-inflammatory drugs (NSAID) have a negative effect on polyp and cancer formation. This review aims to describe some of the mechanism behind the chemoprotective properties of aspirin; COX 2 inhibition, regulation of proliferation and apoptosis and effects on the immune system and also the current evidence that supports its use as a chemoprevention agent against CRC. We will also aim to explore the side effects with the use of aspirin and the pitfalls of using aspirin routinely for primary prophylaxis against CRC.
Item Type:
Article
Language:
en
MeSH:
Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Cost-Benefit Analysis; Humans
ISSN:
1875-5453

Full metadata record

DC FieldValue Language
dc.contributor.authorLee, Chun Sengen_GB
dc.contributor.authorMcNamara, Deirdreen_GB
dc.contributor.authorO'Morain, Colm Aen_GB
dc.date.accessioned2013-07-19T11:09:56Z-
dc.date.available2013-07-19T11:09:56Z-
dc.date.issued2012-11-
dc.identifier.citationAspirin as a chemoprevention agent for colorectal cancer. 2012, 13 (9):1313-22 Curr. Drug Metab.en_GB
dc.identifier.issn1875-5453-
dc.identifier.pmid22493984-
dc.identifier.urihttp://hdl.handle.net/10147/296530-
dc.description.abstractColorectal cancer (CRC) is one of the leading causes of mortality in the western world. It is widely accepted that neoplasms such as colonic polyps are precursors to CRC formation; with the polyp-adenoma-carcinoma sequences well described in medical literature [1, 2]. It has been shown that Aspirin and other non-steroid anti-inflammatory drugs (NSAID) have a negative effect on polyp and cancer formation. This review aims to describe some of the mechanism behind the chemoprotective properties of aspirin; COX 2 inhibition, regulation of proliferation and apoptosis and effects on the immune system and also the current evidence that supports its use as a chemoprevention agent against CRC. We will also aim to explore the side effects with the use of aspirin and the pitfalls of using aspirin routinely for primary prophylaxis against CRC.en_GB
dc.description.urihttp://www.eurekaselect.com/103493/article-
dc.language.isoenen
dc.rightsArchived with thanks to Current drug metabolismen_GB
dc.subject.meshAnimals-
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal-
dc.subject.meshAnticarcinogenic Agents-
dc.subject.meshAspirin-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshCost-Benefit Analysis-
dc.subject.meshHumans-
dc.titleAspirin as a chemoprevention agent for colorectal cancer.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Medicine, Trinity Centre for Health sciences, Adelaide and Meath, Hospital, Dublin, Ireland. chunseng75@yahoo.co.uken_GB
dc.identifier.journalCurrent drug metabolismen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.